Financial News
Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio
Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker’s biopharma PAT portfolio with its well-established products. Financial details were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240104658012/en/
![Tornado’s proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Business Wire)](https://mms.businesswire.com/media/20240104658012/en/1987663/4/Process_Guardian.jpg)
Tornado’s proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Business Wire)
Tornado's patented High-Throughput Virtual Slit (HTVS™) technology measures highest-quality spectra even in difficult Raman analyses. Tornado’s portfolio of Raman analyzers includes the HyperFlux™ PRO Plus, Process Guardian™ and SuperFlux™, all with excellent performance compared to traditional process Raman spectrometers, for more accurate chemical identification and quantification in mixtures and at low concentrations. Tornado analyzers also allow faster measurements of dynamic reactions, and with low laser power they permit safe operation even in hazardous environments.
Tornado’s product line also includes rugged, high-performance Raman probes for immersion, flow cell, non-contact and large-spot measurements, each optimized for different process environments. Tornado analyzers can be multiplexed with a fiber-switch accessory, with one analyzer monitoring up to eight probes at eight different sampling points.
Dr. Andreas Kamlowski, President of Bruker Optics, stated: “The acquisition of Tornado process Raman technology and product is a great fit to expand our range of biopharma PAT analyzers. We warmly welcome the talented Tornado team with valuable applications expertise and years of experience.”
Mr. Ambrish Jaiswal, the CEO of Tornado Spectral Systems, commented: “The Tornado team is proud to join Bruker. We believe that Bruker provides the ideal environment for our ongoing advancements in PAT, and we look forward to further expanding and enhancing Bruker's spectroscopic process portfolio.”
About Tornado Spectral Systems
Founded in 2013, Tornado Spectral Systems designs, manufactures and sells chemical analysis systems based on Raman spectroscopy. Tornado’s non-destructive, real-time measurement solutions offer numerous benefits for established analytical practice and facilitate broader application of Raman methods for pharmaceutical, petrochemical, biotech, and other applications. Tornado’s headquarters is located in Mississauga, Canada, housing sales and marketing, engineering, technical support, and operations. For more information, please visit: https://tornado-spectral.com
About Bruker Corporation
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240104658012/en/
Contacts
Investors:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
+1 (978) 313-5800
Investor.Relations@bruker.com
Media:
Michael Mueller
Marketing Manager
Bruker Optics GmbH & Co. KG
+49 7243 504 2652
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.